title: Effects of a beta blocker and spironolactone on plasma homocysteine levels.
authors.forename: Mehmet E
authors.initials: ME
authors.lastname: Korkmaz
authors.forename: Ilyas
authors.initials: I
authors.lastname: Atar
authors.forename: Egemen
authors.initials: E
authors.lastname: Tayfun
authors.forename: Aylin
authors.initials: A
authors.lastname: Yildirir
authors.forename: Melek
authors.initials: M
authors.lastname: Ulucam
authors.forename: Bülent
authors.initials: B
authors.lastname: Ozin
authors.forename: Haldun
authors.initials: H
authors.lastname: Muderrisoglu
authors.forename: Munire
authors.initials: M
authors.lastname: Turan
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006710:Homocysteine / Q000097:blood* / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D012720:Severity of Illness Index; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D015415:Biomarkers; D004232:Diuretics; D006710:Homocysteine; D013148:Spironolactone; D008790:Metoprolol